The Senate Finance Committee today held a hearing for Alex Azar, President Trump’s nominee for secretary of Health and Human Services. Azar, former president of Lilly USA and deputy HHS secretary under the George W. Bush administration, faced a number of questions from senators about his ties to the pharmaceutical industry and how he would tackle high drug prices. If confirmed, Azar said he would focus his efforts on addressing the high cost of drugs; making health care more affordable, available and “tailored to what individuals want and need in their care”; harnessing “the power of Medicare to shift the focus in our health care system from paying for procedures and sickness to paying for health and outcomes”; and tackling “the scourge of the opioid epidemic.” Tom Price, M.D., resigned as HHS secretary last September. Deputy Secretary Eric Hargan has been serving as acting secretary.

Related News Articles

Headline
The Department of Health and Human Services July 10 released a proposed rule designed to improve health information sharing and interoperability. The Health…
Headline
The Healthcare Equality Network July 3 sent a letter to the Centers for Medicare & Medicaid Services, expressing concerns about claims denials by…
Headline
The Substance Abuse and Mental Health Services Administration June 8 announced the availability of $27.5 million in funding opportunities focused on improving…
Headline
The Department of Health and Human Services July 2 announced it will provide Medicaid and Children's Health Insurance Program coverage to incarcerated people…
Headline
The Department of Health and Human Services’ Office of Inspector General last week announced its intent to investigate Medicare Advantage Organizations’ prior…
Headline
Health and Human Services Secretary Xavier Becerra and the Centers for Medicare & Medicaid Services Administrator Chiquita Brooks-LaSure sent a letter July…